The Medicinal Chemistry of Peptides

被引:108
作者
Nestor, J. J., Jr. [1 ]
机构
[1] EuMederis Pharmaceut Inc, Encinitas, CA 92024 USA
关键词
Peptide; peptide design; peptide pharmaceutical; drug design; medicinal chemistry; constrained peptide; pharmacodynamics; pharmacokinetics; drug depot; GLUCAGON-LIKE PEPTIDE-1; HUMAN GROWTH-HORMONE; CATALYTIC ASYMMETRIC-SYNTHESIS; BIOLOGICALLY-ACTIVE PEPTIDES; CONSTRAINED AMINO-ACIDS; IN-VIVO; ALBUMIN-BINDING; REVERSIBLE LIPIDIZATION; COMPETITIVE ANTAGONISTS; CONFORMATIONAL-ANALYSIS;
D O I
10.2174/092986709789712907
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The shortcomings of native peptides as pharmaceuticals have been long known: short duration of action, lack of receptor selectivity, lack of oral bioavailability. However medicinal chemistry offers solutions to the first two limitations and oral bioavailability issues have been addressed with novel routes of administration (e. g. intranasal, inhalation) and injectable depot formulations. The principal issue for peptide drugs has been a short duration of action, widely assumed to be due to proteolysis. While proteolysis is a problem for native peptide structures, modification of the peptide structure by acylation, PEGylation, unnatural amino acids or restricted conformation can largely remove this issue. However rapid clearance from the blood into the urine remains an issue for even proteolytically stable molecules. Medicinal chemistry approaches here have been peptide modifications to slow release from the injection site (hydrophobic, hydrophilic, self-associating depots), PEGylation, fatty acid acylation, and the like. Medicinal chemistry approaches used in successful peptide pharmaceuticals using unnatural amino acids to achieve depot formation are highlighted in this review.
引用
收藏
页码:4399 / 4418
页数:20
相关论文
共 217 条
[71]   The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin [J].
Havelund, S ;
Plum, A ;
Ribel, U ;
Jonassen, I ;
Volund, A ;
Markussen, J ;
Kurtzhals, P .
PHARMACEUTICAL RESEARCH, 2004, 21 (08) :1498-1504
[72]   Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics [J].
Heitz, Frederic ;
Morris, May Catherine ;
Divita, Gilles .
BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (02) :195-206
[73]   PHARMACOKINETICS AND EFFICACY OF A LONG-ACTING FORMULATION OF THE NEW SOMATOSTATIN ANALOG BIM-23014 IN PATIENTS WITH ACROMEGALY [J].
HERON, I ;
THOMAS, F ;
DERO, M ;
GANCEL, A ;
RUIZ, JM ;
SCHATZ, B ;
KUHN, JM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 76 (03) :721-727
[74]   Foldamers with Heterogeneous Backbones [J].
Horne, W. Seth ;
Gellman, Samuel H. .
ACCOUNTS OF CHEMICAL RESEARCH, 2008, 41 (10) :1399-1408
[75]   Heterocyclic peptide backbone modifications in an α-helical coiled coil [J].
Horne, WS ;
Yadav, MK ;
Stout, CD ;
Ghadiri, MR .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2004, 126 (47) :15366-15367
[77]   Designing peptide receptor agonists and antagonists [J].
Hruby, VJ .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (11) :847-858
[78]   RECENT DEVELOPMENTS IN THE DESIGN OF RECEPTOR SPECIFIC OPIOID-PEPTIDES [J].
HRUBY, VJ ;
GEHRIG, CA .
MEDICINAL RESEARCH REVIEWS, 1989, 9 (03) :343-401
[79]   EMERGING APPROACHES IN THE MOLECULAR DESIGN OF RECEPTOR-SELECTIVE PEPTIDE LIGANDS - CONFORMATIONAL, TOPOGRAPHICAL AND DYNAMIC CONSIDERATIONS [J].
HRUBY, VJ ;
ALOBEIDI, F ;
KAZMIERSKI, W .
BIOCHEMICAL JOURNAL, 1990, 268 (02) :249-262
[80]   Conformation of a peptide ligand bound to its G-protein coupled receptor [J].
Inooka, H ;
Ohtaki, T ;
Kitahara, O ;
Ikegami, T ;
Endo, S ;
Kitada, C ;
Ogi, K ;
Onda, H ;
Fujino, M ;
Shirakawa, M .
NATURE STRUCTURAL BIOLOGY, 2001, 8 (02) :161-165